Tango Therapeutics
TNGX · Nasdaq · United States
Share price · TNGX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when TNGX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 10 Nov 2026+6.9%
- 23 Oct 2026-16.4%
- 21 Oct 2026+6.9%
Nothing announced by TNGX that day or the session before.
- 22 Sep 2026+14.3%
Nothing announced by TNGX that day or the session before.
- 18 Sep 2026-7.4%
Nothing announced by TNGX that day or the session before.
- 9 Sep 2026+5.7%
Nothing announced by TNGX that day or the session before.
- 8 Jun 2026+53.0%
- 15 May 2026-17.3%
Nothing announced by TNGX that day or the session before.
- 5 Mar 2026+36.3%
- 26 Feb 2026-9.7%
Nothing announced by TNGX that day or the session before.
Share of unusual movement by asset
For each asset, the share of TNGX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
Vopimetostatevents and moves
| 2 | shown from 8 days |
| Assets with fewer than 8 event days, together | — | 13% |
| Other company news (earnings, financing, releases naming no asset) | — | 23% |
| Sessions with no dated event | — | 65% |
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | PRMT5Small molecule | Non-Small Cell Lung CancerGlioblastoma | |
| Phase 1/2 | PRMT5Small molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
Discontinued programmes (2)
Development of these assets stopped. Each page states the sourced discontinuation and keeps the trials as evidence history.
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
March 2027 (1)
June 2027 (2)
What to watch
What to watch
2031 (1)
November 2031 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $0 | $49M | $87M+ $891M short-term inv. | $68M-$37M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $0 | $37M | $346M+ $668M short-term inv. | $55M-$39M operating cash flow | report ↗ |
| 2026-Q1 | $0 | $34M | $158M+ $222M short-term inv. | $46M-$44M operating cash flow | report ↗ |
| 2025-Q3 | $54M | $31M | $58M+ $94M short-term inv. | —-$31M operating cash flow | report ↗ |
| 2025-Q2 | $3.2M | $33M | $39M+ $142M short-term inv. | $39M-$37M operating cash flow | report ↗ |
| 2025-Q1 | $5.4M | $36M | $58M+ $158M short-term inv. | $40M-$42M operating cash flow | report ↗ |
| 2024-Q3 | $12M | $33M | $53M+ $240M short-term inv. | $29M-$33M operating cash flow | report ↗ |
| 2024-Q2 | $20M | $39M | $52M+ $271M short-term inv. | $26M-$24M operating cash flow | report ↗ |
| 2024-Q1 | $6.5M | $38M | $61M+ $282M short-term inv. | $38M-$38M operating cash flow | report ↗ |
| 2023-Q3 | $11M | $27M | $59M+ $301M short-term inv. | $22M-$31M operating cash flow | report ↗ |
| 2023-Q2 | $15M | $29M | $66M+ $245M short-term inv. | $21M-$24M operating cash flow | report ↗ |
| 2023-Q1 | $5.8M | $28M | $57M+ $276M short-term inv. | $28M-$35M operating cash flow | report ↗ |
| 2022-Q3 | $6.9M | $29M | $100M+ $293M short-term inv. | $29M-$20M operating cash flow | report ↗ |
| 2022-Q2 | $5.8M | $24M | $105M+ $312M short-term inv. | $25M-$32M operating cash flow | report ↗ |
| 2022-Q1 | $5.8M | $24M | $100M+ $350M short-term inv. | $25M-$30M operating cash flow | report ↗ |
| 2021-Q3 | $6.8M | $22M | $205M+ $299M short-term inv. | $20M-$42M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $62M | $132M | $112M+ $231M short-term inv. | $25M-$139M operating cash flow | report ↗ |
Tango Therapeutics reported full-year 2025 revenue of $62.384M, up 48.3% YoY, with R&D expense of $132.165M, down 8.2% YoY. The company held $112.279M in cash and cash equivalents, or $343.1M including marketable securities, and recorded a full-year net loss of $101.6M, or $0.87 per share, compared with a net loss of $130.3M, or $1.19 per share, in the prior year.
Management guided to a cash runway into 2028. The company is on track to initiate a pivotal vopimetostat monotherapy study in second-line MTAP-deleted pancreatic cancer in 2026, with initial Phase 1/2 data from vopimetostat combined with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib and zoldonrasib also expected in 2026. Tango additionally entered a clinical supply agreement with Erasca to evaluate vopimetostat with ERAS-0015, and expects initial Phase 1/2 data for TNG456 in 2026. Corporate developments included the succession of Malte Peters as CEO, the appointment of Philippe Serrano as Chief Regulatory Officer, and the addition of Sung Lee to the board.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $42M | $144M | $70M+ $188M short-term inv. | $33M-$132M operating cash flow | report ↗ |
| 2023-FY | $37M | $115M | $66M+ $271M short-term inv. | $25M-$118M operating cash flow | report ↗ |
| 2022-FY | $25M | $106M | $60M+ $306M short-term inv. | $27M-$109M operating cash flow | report ↗ |
| 2021-FY | $37M | $78M | $143M+ $343M short-term inv. | $15M-$60M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 31 sales ($8.2M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-17 | Ketchum John B · director | Open-market sale | 3,333 | $24.08 | $80K | Form 4 |
| 2026-11-11 | Crystal Adam · President, R&D | Option exercise | 5,000 | $2.91 | $15K | Form 4 |
| 2026-11-11 | Crystal Adam · President, R&D | Open-market sale | 5,000 | $25.00 | $125K | Form 4 |
| 2026-11-11 | Crystal Adam · President, R&D | Option exercise (derivative) | 5,000 | — | — | Form 4 |
| 2026-11-02 | Newcomb Jessica · Principal Accounting Officer | Open-market sale | 5,571 | $22.28 | $124K | Form 4 |
| 2026-11-02 | Crystal Adam · President, R&D | Option exercise | 5,000 | $2.91 | $15K | Form 4 |
| 2026-11-02 | Newcomb Jessica · Principal Accounting Officer | Open-market sale | 1,460 | $22.98 | $34K | Form 4 |
| 2026-11-02 | Crystal Adam · President, R&D | Open-market sale | 3,900 | $22.26 | $87K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 194 reporting institutions held 180.5M shares ($3.7B, 106.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 13,300,620 | $278.2M |
| 2 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 12,809,485 | $268.0M |
| 3 | Boxer Capital Management, LLC | 10,876,219 | $227.5M |
| 4 | TCG Crossover Management, LLC | 10,531,071 | $220.3M |
| 5 | FMR LLC | 9,905,919 | $207.2M |
| 6 | FARALLON CAPITAL MANAGEMENT LLC | 9,097,411 | $190.3M |
| 7 | BlackRock, Inc. | 8,748,045 | $183.0M |
| 8 | Woodline Partners LP | 8,000,013 | $167.4M |
| 9 | Nextech Invest, Ltd. | 7,266,081 | $152.0M |
| 10 | TRV GP IV, LLC | 6,374,574 | $133.4M |
| 11 | Siren, L.L.C. | 5,657,105 | $118.3M |
| 12 | VANGUARD CAPITAL MANAGEMENT LLC | 5,161,431 | $108.0M |
| 13 | GOLDMAN SACHS GROUP INC | 5,076,392 | $106.2M |
| 14 | STATE STREET CORP | 4,651,894 | $97.3M |
| 15 | DEERFIELD MANAGEMENT COMPANY, L.P. | 4,146,813 | $86.8M |